Emily C Von Bargen1,2, Cara L Grimes3, Kavita Mishra4, Rui Wang2,5, Miriam J Haviland2,5, Michele R Hacker2,5, Joseph A Carnevale4, Alyssa J Estes6, Eman A Elkadry1,2. 1. Department of Obstetrics and Gynecology, Mount Auburn Hospital, Harvard Medical School affiliate, Cambridge, MA, USA. 2. Beth Israel Deaconess Medical Center, Harvard Medical School affiliate, Boston, MA, USA. 3. Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA. 4. Department of Obstetrics and Gynecology, Brown University, Providence, RI, USA. 5. Harvard Medical School, Boston, MA, USA. 6. Touro College of Osteopathic Medicine, New York, NY, USA.
Abstract
OBJECTIVE: To determine the prevalence of occult pre-malignant or malignant uterine pathology at the time of laparoscopic surgery with open power morcellation for benign gynecologic disease. METHODS: The present multicenter, retrospective cohort study included women who underwent open power morcellation for benign indications between January 1, 2007, and February 28, 2014, at three academic medical centers in the USA. The primary outcome was pre-malignant or malignant pathology at the time of open power morcellation, and was determined from the patients' pathology reports. RESULTS: During the study period, 1214 women underwent open power morcellation for benign indications. Similar preoperative characteristics were observed between patients with normal pathology and those with pre-malignant or malignant uterine pathology, including body mass index, parity, hypertension, diabetes, breast cancer, and smoking (all P>0.129). Among patients who underwent open power morcellation, 14 (1.2%) had occult pre-malignant or malignant pathology; 5 (0.4%) women had endometrial adenocarcinoma and 1 (0.1%) had low-grade endometrial stromal sarcoma. There were eight patients with malignant pathology who underwent additional surgical exploration and were disease free at their final clinical visit, with a median follow-up time of 42.0 months (interquartile range 5.0-62.0 months). CONCLUSION: Endometrial adenocarcinoma and low-grade endometrial stromal sarcoma were rare in the present study and there were no reports of leiomyosarcoma.
OBJECTIVE: To determine the prevalence of occult pre-malignant or malignant uterine pathology at the time of laparoscopic surgery with open power morcellation for benign gynecologic disease. METHODS: The present multicenter, retrospective cohort study included women who underwent open power morcellation for benign indications between January 1, 2007, and February 28, 2014, at three academic medical centers in the USA. The primary outcome was pre-malignant or malignant pathology at the time of open power morcellation, and was determined from the patients' pathology reports. RESULTS: During the study period, 1214 women underwent open power morcellation for benign indications. Similar preoperative characteristics were observed between patients with normal pathology and those with pre-malignant or malignant uterine pathology, including body mass index, parity, hypertension, diabetes, breast cancer, and smoking (all P>0.129). Among patients who underwent open power morcellation, 14 (1.2%) had occult pre-malignant or malignant pathology; 5 (0.4%) women had endometrial adenocarcinoma and 1 (0.1%) had low-grade endometrial stromal sarcoma. There were eight patients with malignant pathology who underwent additional surgical exploration and were disease free at their final clinical visit, with a median follow-up time of 42.0 months (interquartile range 5.0-62.0 months). CONCLUSION:Endometrial adenocarcinoma and low-grade endometrial stromal sarcoma were rare in the present study and there were no reports of leiomyosarcoma.
Authors: John A Harris; Carolyn W Swenson; Shitanshu Uppal; Neil Kamdar; Nichole Mahnert; Sawsan As-Sanie; Daniel M Morgan Journal: Am J Obstet Gynecol Date: 2015-08-24 Impact factor: 8.661
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jason D Wright; Thomas J Herzog; Jennifer Tsui; Cande V Ananth; Sharyn N Lewin; Yu-Shiang Lu; Alfred I Neugut; Dawn L Hershman Journal: Obstet Gynecol Date: 2013-08 Impact factor: 7.661
Authors: Matthew T Siedhoff; Stephanie B Wheeler; Sarah E Rutstein; Elizabeth J Geller; Kemi M Doll; Jennifer M Wu; Daniel L Clarke-Pearson Journal: Am J Obstet Gynecol Date: 2015-03-24 Impact factor: 8.661
Authors: Elizabeth A Pritts; David J Vanness; Jonathan S Berek; William Parker; Ronald Feinberg; Jacqueline Feinberg; David L Olive Journal: Gynecol Surg Date: 2015-05-19